Tradjenta
Lilly and Boehringer diabetes drug sees US launch
March 24, 2015Sales and Marketing Boehringer, Glyxambi, Tradjenta, diabetes, empagliflozin/linagliptin, lilly, linagliptin
Lilly and Boehringer Ingelheim’s combo diabetes drug Glyxambi is now available to treat adult patients in the US. Glyxambi (empagliflozin/linagliptin) …
Boehringer and Lilly score FDA yes for Glyxambi
February 3, 2015Sales and Marketing Boehringer, FDA, Glyxambi, Tradjenta, empagliflozin, jardiance, lilly, linagliptin
The FDA has approved Glyxambi (empagliflozin/linagliptin), which has become the first combination of two diabetes drugs in their different classes …
Boehringer hands back Lilly drug
January 8, 2013Research and Development, Sales and Marketing Boehringer, Tradjenta, diabetes, lilly
Boehringer Ingelheim has handed back one of Eli Lilly’s investigational diabetes drugs as a result of ‘independent strategic portfolio considerations’. …
Boehringer-Lilly won’t launch Trajenta in Germany
September 5, 2011Sales and Marketing Drug pricing, Germany, Tradjenta, Trajenta, price cuts
Boehringer Ingelheim and Lilly have decided not to launch their new diabetes drug Trajenta in Germany and say the country’s …
Boehringer-Lilly’s Trajenta wins European approval
August 26, 2011Sales and Marketing Tradjenta, Trajenta, diabetes
Boehringer Ingelheim and Eli Lilly’s new type II diabetes drug Trajenta has been approved Europe. The European Commission backed Trajenta …
CHMP backs Boehringer-Lilly diabetes drug Trajenta
June 27, 2011Sales and Marketing Tradjenta, Trajenta, diabetes
Boehringer Ingelheim and Eli Lilly’s new type II diabetes drug Trajenta has been recommended for European approval. It was given …
Boehringer-Lilly launch diabetes drug Tradjenta in US
June 16, 2011Sales and Marketing Boehringer Ingelheim, Tradjenta, diabetes, lilly
Boehringer Ingelheim and Eli Lilly’s new type II diabetes treatment Tradjenta has been launched in the US. Tradjenta (linagliptin) is …
US approval for Boehringer’s diabetes drug Tradjenta
May 3, 2011Sales and Marketing Boehringer Ingelheim, Tradjenta, diabetes, lilly
Tradjenta, the once-daily oral type II diabetes treatment developed by Boehringer Ingelheim, has been approved by US regulators. The FDA …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
